IfW

I hereby certify that the pondence is being deposited with the U.S. Postal Service with sufficient postage as. First Class Mail, in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 3, 2007

Signature (Sharon M Sintich)

Docket No.: 30847/2051-004

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Anna Helgadottir et al.

Filed: January 30, 2004

Confirmation No.: 6429 Application No.: 10/769,744

Art Unit: 1634

Examiner: D. Johannsen

For: SUSCEPTIBILITY GENE FOR

MYOCARDIAL INFARCTION, STROKE, AND PAOD; METHODS OF TREATMENT

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the reference listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom. A copy of document C134 is enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art."

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37

Application No.: 10/769,744 Docket No.: 30847/2051-004

CFR 1.97(b)(3)). Accordingly, no fees are believed to be due. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30847/2051-004. A duplicate copy of this paper is enclosed.

Dated: May 3, 2007

Respectfully submitted

Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agent for Applicants

		SHEET 1 of 1
Form PTO-1449 (Modified)	Atty. Docket No.	Serial No.
	30847/2051-004	10/769,744
INTODMATION DISCLOSUDE STATEMENT	Applicant(s)	
INFORMATION DISCLOSURE STATEMENT	Anna Helgadottir et al.	
	Filing Date	Art Unit
MAY 0 7 2007	January 30, 2004	1634
WAY O 1 Soon		

U.S. PATENT DOCUMENTS							
Examiner Initials	Document Number	Issue or Publication Date	Name		Class	Subclass	Filing Date (If Appropriate)
				:			

FOREIGN PATENT DOCUMENTS				
Examiner Initials	Document Number	Publication Date	Country	Translation Yes No
			1	

	OTHER DOCUMENTS
C134	Morgan et al., Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study, J. Amer. Med. Assoc., 297: 1551-1561 (April 11, 2007).

EXAMINER:	•	DATE CONSIDERED:	